DOCSLIB.ORG

Keyword Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

202 KEYWORD INDEX Keyword index A Death, 109 Emergency Department, 318 Addiction, 15 Deaths, 59 Emergency Departments, 270 agitation, 5 decontamination, 118 emergency medicine residents, 70 Alcohol Intoxication, 8 deferoxamine, 203 emergency medicine, 317 alcohol, 5 delirium, 27 emergency medicine, 64 Anticholinergic, 4 Derm, 248 Emergency Preparedness, 235 Antivenom, 16 dermal injury, 217 Emergency Preparedness, 52 arrhythmia, 7 Desiccant, 150 envenomation, 100 artificial intelligence, 11 dextromethorphan, 163 envenomation, 101 Dextromethorphan, 237 Envenomation, 108 B dextromethorphan, 285 envenomation, 143 bupropion, 12 dialysis, 154 envenomation, 155 Dialysis, 71 Envenomation, 25 C dietary supplements, 244 Envenomation, 307 cardiotoxicity, 12 diethylene glycol, 6 Envenomation, 31 charges, 13 Differential diagnosis, 11 envenomation, 43 compatibility, 2 Dimercaptosuccinic acid (DMSA, succi- Envenomation, 45 coronavirus, 236 mer), 111 envenomation, 98 Coronavirus, 35 dimercaptosuccinic acid, 130 envenomation, 99 coronavirus, 87 diphacinone, 230 Epidemic, 37 Covid 19, 57 disinfectants, 57 Epidemiology, 245 COVID-19 Hotline, 235 DMSA, 130 epidemiology, 254 COVID-19, 115 dosing, 273 Epidemiology, 295 COVID-19, 181 Double-peak, 238 epinephrine, 286 COVID-19, 192 Drug abuse, 158 Esophageal obstruction, 150 COVID-19, 214 drug abuse, 17 Essential oil, 141 COVID-19, 245 drug misuse, 17 Essential Oils, 139 COVID-19, 249 Drug misuse, 9 Essential oils, 140 COVID-19, 253 Drug Screening, 199 Essential oils, 177 Covid-19, 258 Drug therapy monitoring, 190 Ethosuximide, 137 COVID-19, 261 Drug-Induced, 85 Ethylene Glycol, 54 COVID-19, 262 Drugs of Abuse, 221 ethylene glycol, 97 COVID-19, 263 Drugs of Abuse, 222 etoh, 252 COVID-19, 30 Drugs of misuse, 271 Eugenol, 26 COVID-19, 306 Dysrhythmias, 53 EVALI, 133 CoVID-19, 41 EVALI, 82 CoVID-19, 42 E expanding polymer beads, 184 covid-19, 58 eCigarette exposure, 10 exploratory ingestion, 1 COVID-19, 94 E-Cigarette, 82 Exploratory Ingestion, 88 Critical Access Hospital, 277 Ecstasy, 292 explosive, 304 Critical Care, 179 Education, 191 Exposure Cases, 249 crofab, 170 Education, 257 Exposure Cases, 306 Crotaline envenomation, 176 EKG, 134 Extracorporeal Membrane Oxygenation, Crush injury, 283 elapidae, 128 188 Cyanide, 24 Elderly, 24 EXTRIP, 71 Cyanide, 276 Electronic Nicotine Delivery Systems, 79 EXTRIP, 72 cyclonite, 304 Elemental mercury poisoning, 40 Elimination, 137 F D Embolism, 138 Factitious disorder, 310 Dapsone, 29 Embolism, 81 factitious, 161 Death Camas, 234 Emergency department, 116 false, 97 CLINICAL TOXICOLOGY 203 Fasciotomy, 283 hotline, 236 Lacrimators, 267 Fatal intentional ingestion, 308 Human Exposures, 247 lactate, 97 fatality, 135 hydrocarbon, 208 lactic acidosis, 159 Fatality, 265 Hydrocarbon, 287 Lactic Acidosis, 206 FDA Adverse Event Reporting System, Hydrocodone, 224 lamp oil, 208 119 Hydrogen Peroxide, 138 language barrier, 92 FDA, 288 Hydrogen Peroxide, 47 language, 92 Fentanyl analogs, 316 Hydrogen Peroxide, 81 Laundry detergent, 116 fentanyl, 102 Hydromorphone, 78 Laundry pods, 116 fentanyl, 202 Hydroxocobalamin, 276 Law Enforcement, 37 Fentanyl, 222 hydroxychloroquine, 115 lead poisoning, 21 Fentanyl, 271 hydroxychloroquine, 300 lead, 130 Fentanyl, 73 hydroxyzine, 136 Lead, 290 fire inhalation, 48 Hydroxyzine, 229 lead, 312 flower, 172 Hyperbaric Oxygen Therapy, 81 length of stay, 13 Flumazenil, 110 hypercalcemia, 91 Lepidopterism, 107 flumazenil, 204 Hyperthermia, 38 Levomilnacipran, 147 Fluorinated hydrocarbons, 112 Hyperthermia, 85 levothyroxine, 239 Fly agaric mushrooms, 22 Hypoglycemia, 123 levothyroxine, 240 Follow-up, 287 hypoklemia, 161 Lidocaine, 122 Fomepizole, 156 hypothermia, 132 liothyronine, 239 Football, 247 Hypothermia, 38 liothyronine, 240 Foraging, 258 Liposuction, 122 foreign body, 117 I liquid chromatography-mass spectrom- Fumigants and rodenticides, 114 ibuprofen, 27 etry (LC-MS), 50 FYCOMPA, 182 Illicit drugs, 105 Liquid Laundry Detergent Packs, 315 Imovax®, 268 liquid nicotine, 314 G Indian hawthorn, 62 Liquid Nicotine, 49 gabapentin, 17 Indirect, 59 lithium poisoning, 186 Gas Emboli, 47 infant, 149 Lithium, 71 geriatrics, 145 Infants, 233 Lithium, 72 gliflozins, 28 Information Cases, 306 liver function, 89 glow product, 120 ingestion, 3 Longitudinal Data Linkage, 8 Goofball, 298 Inhalant abuse, 112 Loperamide, 165 Guanfacine, 148 inhalational methanol toxicity, 174 loperamide, 218 Guanfacine, 33 Initial control, 176 Lorazepam, 4 guanidine thiocyanate, 243 Inorganic mercury, 111 low utilization areas, 256 Guinea, 45 Insulin, 123 Loxosceles, 248 Intentional Overdose, 229 lupini bean, 18 H intentional overdose, 259 Lurasidone, 86 Haff disease, 291 intentional, 230 hand sanitizers, 57 intentionally poisoned, 91 M Healthcare providers, 14 Interactive Voice Response, 235 Machine learning, 11 Heaping teaspoon, 41 Interprofessional education, 39 Magnesium, 153 Heloderma, 260 Intoxication, 253 magnet, 1 hemodialysis, 174 intravenous, 19 magnet, 3 hemolysis, 126 iron sucrose, 203 Malicious Overdose, 123 Hepatotoxicity, 156 iron, 203 Management, 53 Herbal pills, 74 irrigation, 118 Manganese, 67 Heroin, 221 ivermectin, 149 Marijuana vaping products, 10 Heroin, 271 marijuana, 201 high-dose diazepam, 300 K Marijuana, 302 High-powered magnet, 1 Ketorolac, 191 marijuana, 68 high-resolution Mass spectrumetry, 316 kratom, 168 marijuana, 69 Hippocampus, 309 Kratom, 283 Massive, 55 Hispanic, 254 kratom, 90 massive, 77 homemade slime, 171 Mass-market, 55 L hookah smoking, 23 MDMA, 292 lacquer thinner, 174 Hookah, 226 MDMA, 85 204 KEYWORD INDEX media outreach, 256 Naloxone, 78 oral anesthetics, 113 Medical outcome, 177 National Electronic Injury Surveillance Over the counter, 14 medication error, 175 System, 120 overdose prevention, 209 Medication Error, 78 National Electronic Injury Surveillance overdose, 102 medication packaging, 165 System, 171 Overdose, 179 medication safety, 159 National Poison Data System, 219 Overdose, 180 medication safety, 160 National Poison Data System, 222 Overdose, 197 Medication-Assisted Treatment, 15 National Poison Data System, 223 overdose, 210 Melia azedarach, 269 National Poison Data System, 225 overdose, 231 mercury poisoning, 215 nebivolol, 231 Overdose, 238 metformin, 159 neonate, 95 overdose, 246 Metformin, 74 Nepal, 216 overdose, 264 Methadone, 262 nephropathy, 215 overdose, 27 Methadone, 32 nephrotoxicity, 6 overdose, 293 methaemoglobin, 126 Neuropsychiatric effects, 292 Overdose, 55 Methamphetamine, 193 neurotoxicity, 232 overdose, 61 methamphetamine, 194 Neurotoxicity, 307 overdose, 64 Methamphetamine, 295 neurotoxicity, 6 Overdose, 80 Methamphetamine, 296 Neurotoxicity, 67 overdoses, 195 Methamphetamine, 298 New psychoactive subtsances, 9 Oxycodone, 220 Methamphetamine, 299 Nicotine, 79 Methamphetamine, 37 Nomogram, 72 P methamphetamine, 5 Non-medical use, 14 pandemic, 129 Methanol, 54 Novel drugs, 158 Pandemic, 52 Methemoglobin, 276 NPDS, 200 pandemic, 58 methemoglobinemia, 113 NPH insulin, 241 Paracetamol, 303 Methemoglobinemia, 166 NSDUH, 224 paradichlorobenzene, 232 Methemoglobinemia, 185 Nux Vomica, 76 paradigm shift, 94 methemoglobinemia, 214 parenteral, 243 Methemoglobinemia, 29 O Parkinsonism, 67 Methomyl, 121 Observation, 138 Pediatric Emergency Medicine, 157 methotrexate, 273 Observation, 193 Pediatric Exposures, 315 Methylene Blue, 185 Occupational exposure, 146 pediatric patient, 175 methylene chloride, 217 occupational exposure, 217 Pediatric Poisoning, 49 micro-preemie, 95 Ocular symptoms, 51 pediatric toxicology, 184 military hospital, 294 oleander, 172 Pediatric toxicology, 29 military, 304 ondansetron, 198 Pediatric, 110 Milnacipran, 147 Online Information Syste, 66 pediatric, 144 mitragynine, 132 Online simulation, 39 pediatric, 149 mitragynine, 168 online, 211 pediatric, 152 model of care, 124 Operations, 266 pediatric, 163 Mortality, 219 Opiate Substitution Treatment, 318 pediatric, 178 Munchausen’s, 310 Opiate, 237 pediatric, 181 Mushroom Toxicity, 22 Opioid analgesics, 228 pediatric, 187 Mushroom, 287 opioid crisis, 56 pediatric, 19 Myokymia, 250 opioid overdose, 227 pediatric, 208 opioid reversal, 64 pediatric, 210 N opioid treatment, 90 Pediatric, 213 N-acetylcysteine, 109 Opioid use disorder, 192 Pediatric, 250 N-acetylcysteine, 26 opioid, 102 pediatric, 286 N-acetylcysteine, 77 opioid, 173 pediatric, 3 N-acetylcysteine, 89 opioid, 210 pediatric, 32 N-acetylcysteine, 95 opioid, 246 Pediatric, 62 N-Acetylcystine, 164 opioid, 294 pediatric, 69 naloxone, 204 Opioid, 309 Pediatric, 88 naloxone, 209 Opioids, 219 Pediatrics, 199 naloxone, 264 Opioids, 225 Pediatrics, 200 naloxone, 305 Opioids, 297 pediatrics, 201 naloxone, 317 Opioids, 298 pediatrics, 202 CLINICAL TOXICOLOGY 205 Pediatrics, 33 Poisoning, 177 Rattlesnake, 16 Pepper spray, 270 Poisoning, 188 Rattlesnake, 196 perampanel, 180 Poisoning, 213 Rattlesnake, 228 Permpanel, 182 Poisoning, 253 Rattlesnake, 250 pharmacist, 160 poisoning, 254 Rattlesnake, 278 Pharmacokinetics, 188 Poisons, 79 Rattlesnake, 279 Phencyclidine, 200 policy, 165 Rattlesnake, 280 Phenformin, 74 Pollyanna, 83 Rattlesnake, 281 Phenibut, 251 polyvalent snake antivenom, 20 Rattlesnake, 31 phenol, 243 postmortem redistribution, 314 rattlesnake, 43 Phosphides, 114 postmortem, 135 Recreational drugs, 103 Phosphine gas, 114 potassium binder, 186 recurrence, 98 physostigmine, 187 Predictors of Misuse, 224 Regional Poison Center, 65 physostigmine, 2 Pregnancy, 140 remote agent, 94 Physostigmine, 229 PRES, 233 renal clearance, 160 Physostigmine, 4 prescribing, 317 renal injury,
Recommended publications
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD

    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD April 2015 CONTENTS General Toxicology 9 Metals 44 Management 22 Pesticides 49 Drugs 23 Chemical Warfare 51 Chemical Incidents & 36 Plants 52 Pollution Chemicals 37 Animals 52 CURRENT AWARENESS PAPERS OF THE MONTH Acute toxicity profile of tolperisone in overdose: observational poison centre-based study Martos V, Hofer KE, Rauber-Lüthy C, Schenk-Jaeger KM, Kupferschmidt H, Ceschi A. Clin Toxicol 2015; online early: doi: 10.3109/15563650.2015.1022896: Introduction Tolperisone is a centrally acting muscle relaxant that acts by blocking voltage-gated sodium and calcium channels. There is a lack of information on the clinical features of tolperisone poisoning in the literature. The aim of this study was to investigate the demographics, circumstances and clinical features of acute overdoses with tolperisone. Methods An observational study of acute overdoses of tolperisone, either alone or in combination with one non-steroidal anti-inflammatory drug in a dose range not expected to cause central nervous system effects, in adults and children (< 16 years), reported to our poison centre between 1995 and 2013. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Results 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults (60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children (33%).
  • Annual Meeting Abstracts

    Annual Meeting Abstracts

    J. Med. Toxicol. (2012) 8:192–237 DOI 10.1007/s13181-012-0237-z ANNUAL MEETING ABSTRACTS Annual Meeting Abstracts Published online: 26 May 2012 © American College of Medical Toxicology 2012 The following are the abstracts from the scientific presenta- 2Department of Mathematics, Faculty of Engineering, tions of the 10th Annual Congress of the Asia-Pacific As- University of Moratuwa, Moratuwa, Sri Lanka. sociation of Medical Toxicology (APAMT), which was held 3Department of Medical Laboratory Sciences, Faculty of in Penang, Malaysia, in November 2011. Clinicians and Allied Health Sciences, University of Peradeniya, Peradeniya, researchers from over 20 countries attended this meeting, Sri Lanka where more than 110 abstracts were showcased as either oral platform or poster presentations. Introduction: Chronic kidney disease due to unknown ae- Nine young investigators from across the Asia-Pacific tiology (CKD-U) is one of the growing health problems in region were given scholarships to attend the meeting Sri Lanka. About 8,000 diagnosed CKD-U patients are and to present their research as oral presentations. Their enduring treatment in the country largely in the North Cen- talks were mixed in with invited presentations on sub- tral Region (NCR). Ninety percent (90 %) of the patients are jects relevant to Asia, including Chinese and Ayurvedic farmers. medicine toxicity, snake systematics and venom, phar- Objectives: The study is designed to calculate an agricul- macovigilance, two plenary talks by recipients of tural risk index for an individual who lives in high risk areas APAMT Honorary Fellowships, and high-quality clinical of the country. and public health research. Two very successful sympo- Methods and Materials: The study is a case–control study sia were held on fomepizole use and on recreational and 315 CKD-U patients and 321 normal healthy individu- drug use in Asia-Pacific (hosted by American College als were randomly selected from NCR.
  • Methanol Interim AEGL Document

    Methanol Interim AEGL Document

    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
  • Methanol: Toxicological Overview

    Methanol: Toxicological Overview

    Methanol Toxicological Overview Key Points Kinetics and metabolism readily absorbed by all routes and distributed in the body water undergoes extensive metabolism, but small quantities are excreted unchanged by the lungs and in the urine Health effects of acute exposure methanol is toxic following ingestion, inhalation or dermal exposure exposure may initially result in CNS depression, followed by an asymptomatic latent period metabolic acidosis and ocular toxicity, which may result in blindness, are subsequent manifestations of toxicity coma and death may occur following substantial exposures long-term effects may include blindness and, following more substantial exposures, permanent damage to the CNS Health effects of chronic exposure long-term inhalation exposure to methanol has resulted in headaches and eye irritation in workers methanol is considered not to be a mutagen or carcinogen in humans methanol is considered not to be a reproductive toxicant in humans PHE publications gateway number: 2014790 Published: August 2015 Compendium of Chemical Hazards: Methanol Summary of Health Effects Methanol may be acutely toxic following inhalation, oral or dermal exposure. Acute methanol toxicity often follows a characteristic series of features; initially central nervous system (CNS) depression and gastrointestinal tract (GI) irritation may be observed. This is typically followed by a latent period of varying duration from 12–24 hours and occasionally up to 48 hours. Subsequently, a severe metabolic acidosis develops with nausea, vomiting and headache. Ocular toxicity ranges from photophobia and misty or blurred vision to markedly reduced visual acuity and complete blindness following high levels of exposure. Ingestion of as little as 4–10 mL of methanol in adults may cause permanent damage.
  • Revista Brasileira De Anestesiologia

    Revista Brasileira De Anestesiologia

    Rev BrasBras Anestesiol. Anestesiol. 2013;63(1):163–164 2013;63(1):163-166 REVISTA BRASILEIRA DE ANESTESIOLOGIA Offi cial Publication of the Brazilian Society of Anesthesiology www.sba.com.br/rba/index.asp LETTER TO THE EDITOR Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine Dear Editor, furosemide (10 mg.mL-1), gentamicin (40 mg.mL-1), glyceryl Sugammadex is a modifi ed gamma cyclodextrin 1-3. Cyclodextrins trinitrate (5 mg.mL-1), heparin (1,000 IU.mL-1), hydrocor- are water soluble cyclic oligosaccharides with a lipophilic tisone (250 mg.mL-1), crystallized insulin (100 IU.mL-1), core. Sugammadex has quickly found a place in clinical use Calcium (Calcium Gluconate Monohydrate 225 mg.10 mL-1 for selective antagonism of neuromuscular blockade with ro- + Calcium levulinate dihitrate 572 mg.10 mL-1), ketamine curonium 1-3. Sugammadex quickly encapsulates steroidal neu- (50 mg.mL-1), levobupivacaine (7.5 mg.mL-1), magnesium romuscular blockers, increasing the amount of encapsulated sulphate (1.2 mEq.mL-1), metamizol sodium (0.5 g.mL-1), steroidal neuromuscular blockers in plasma and separating the methylergobasin maleate (0.2 mg.mL-1), metoclopramide blockers from the nicotinic acetylcholine receptors 1-3. (5 mg.mL-1), metoprolol (1 mg.mL-1), morphine (0.01 g.mL-1), Apart from its use with steroidal neuromuscular block- midazolam (5 mg.mL-1), n-acetylcysteine (100 mg.mL-1), ers, it is known that sugammadex interacts with over 40 naloxone (0.4 mg.mL-1), neostigmine (0.5 mg.mL-1), nitroprus- lipophilic, steroidal and non-steroidal drugs.
  • PHARMACOLGY HOMEWORK Overdose Management Add In

    PHARMACOLGY HOMEWORK Overdose Management Add In

    PHARMACOLGY HOMEWORK Overdose Management Add in important nursing notes for each of these medications and overdose management as well as administration route. Medication Overdose Nursing Notes (*Homework) Management (Routes) Acetaminophen Acetylcysteine Acetaminophen: (PO/PR) Route: PO, IV Max daily dose: 4000mg Acute toxicity (overdose) Monitor for S+S of hepatotoxicity (éLFTs, bilirubin, hypoglycemia, renal damage) Acetylcysteine: IV infusion: monitor for fluid overload and signs of hyponatremia such as changes in mental status Monitor for S+S of aspiration, bronchospasm, excess secretions Digitalis Digoxin Immune Fab Digoxin: (PO/IV) (Ovine, Digibind) Take apical pulse for 60sec. If < 60 BPM hold Route: IV digoxin dose and contact prescriber. Monitor serum digoxin (it has a narrow therapeutic index), potassium, magnesium, calcium. Monitor for S+S toxicity: anorexia, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias Digoxin Immune Fab: Skin allergy testing prior to administration for history of allergy or previous therapy of this drug Monitor cardiac status + rhythm, neurological status Toxicity reversal within an hour (adults), minutes (children) of antidote administration Monitor serum potassium, critical within first few hours; serum digoxin levels, ECG for 2-3 weeks post administration Heparin Protamine sulfate Heparin: (IV/SC) (IV) Monitor for spontaneous bleeding, thrombocytopenia Monitor aPTT levels Protamine Sulfate: Sudden drop in BP Monitor BP+ P q15-30 min Monitor aPTT Opioid Naloxone (IV-adults, Opioids:
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants

    Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants

    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
  • Protamine Characterization by Top-Down Proteomics: Boosting Proteoform Identification with DBSCAN

    Protamine Characterization by Top-Down Proteomics: Boosting Proteoform Identification with DBSCAN

    proteomes Article Protamine Characterization by Top-Down Proteomics: Boosting Proteoform Identification with DBSCAN Gianluca Arauz-Garofalo 1, Meritxell Jodar 2,3 , Mar Vilanova 1, Alberto de la Iglesia Rodriguez 2, Judit Castillo 2 , Ada Soler-Ventura 2, Rafael Oliva 2,3,* , Marta Vilaseca 1,* and Marina Gay 1,* 1 Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain; [email protected] (G.A.-G.); [email protected] (M.V.) 2 Molecular Biology of Reproduction and Development Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per a la Recerca Biomèdica (FCRB), Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain; [email protected] (M.J.); [email protected] (A.d.l.I.R.); [email protected] (J.C.); [email protected] (A.S.-V.) 3 Biochemistry and Molecular Genetics Service, Hospital Clínic de Barcelona, 08036 Barcelona, Spain * Correspondence: [email protected] (R.O.); [email protected] (M.V.); [email protected] (M.G.) Abstract: Protamines replace histones as the main nuclear protein in the sperm cells of many species and play a crucial role in compacting the paternal genome. Human spermatozoa contain protamine 1 (P1) and the family of protamine 2 (P2) proteins. Alterations in protamine PTMs or the P1/P2 ratio Citation: Arauz-Garofalo, G.; may be associated with male infertility. Top-down proteomics enables large-scale analysis of intact Jodar, M.; Vilanova, M.; proteoforms derived from alternative splicing, missense or nonsense genetic variants or PTMs.
  • Spread of Alimentary-Toxic Paroxysmal Myoglobinuria-Haff Disease (Literature Review)

    Spread of Alimentary-Toxic Paroxysmal Myoglobinuria-Haff Disease (Literature Review)

    E3S Web of Conferences 254, 09002 (2021) https://doi.org/10.1051/e3sconf/202125409002 FARBA 2021 Spread of alimentary-toxic paroxysmal myoglobinuria-haff disease (literature review) L.A. Glazunova*, A.R. Musina, A.A. Yurchenko, Y.V. Glazunov, and E.M. Gagarin Federal State Budgetary Educational Institution of Higher Education Northern Trans-Ural State Agricultural University, Tyumen, Russia Abstract. In 1924, Haff disease was first detected in East Prussia. Till now, cases of Haff disease have been recorded in Sweden, Russia, the United States, China, Brazil, Japan, and China among people and animals. During the last 40 years, there has been a significant expansion in the geographical range of Haff disease. From 1924 to 2019, 31 outbreaks were recorded in various parts of the world. The total number of victims was about 3,000 people. In Russia, the last cases of human disease were registered in 2019- 2020. In fact, the source of the toxin is fish (crucian carp, carp, pike, burbot, walleye, perch, ruff, ide, yellowtail, black sea bass, eel, silver dollar, brown paku, red paku, cowfish, etc.) or crayfish. Today, the problem of the disease etiology has not been solved; the toxin with the corresponding features has not been isolated, and as a result, causal and pathogenetic treatment of alimentary-toxic paroxysmal myoglobinuria has not been developed. Over this period, several hypotheses were made that are leading in the study of the etiology of the occurrence of Haff disease (thiaminase theory, tannic, arachidonic). This disease-causing substance is known to be heat-resistant and break down the metabolism of skeletal muscles, resulting in the release of myoglobin, which disorders kidney function.
  • METHANOL 6 (CAS Reg

    METHANOL 6 (CAS Reg

    1 INTERIM 1: 1/2003 2 INTERIM 2: 2/2005 3 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS 4 (AEGLs) 5 METHANOL 6 (CAS Reg. No. 67-56-1) 7 For 8 NAS/COT Subcommittee for AEGLs 9 February 2005 METHANOL Interim 2: 2/2005 10 PREFACE 11 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the 12 National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 13 (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and 14 other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 15 AEGLs represent threshold exposure limits for the general public and are applicable to emergency 16 exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as 17 appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 18 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the 19 recommended exposure levels are applicable to the general population including infants and children, and 20 other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: 21 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 22 is predicted that the general population, including susceptible individuals, could experience notable 23 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling 24 and are transient and reversible upon cessation of exposure.
  • International Classification of Diseases

    International Classification of Diseases

    INTERNATIONAL CLASSIFICATION OF DISEASES MANUAL OF THE INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES, INJURIES, AND CAUSES OF DEATH Based on the Recommendations of the Eighth Revision Conference, 1965, and Adopted by the Nineteenth World Health Assembly Volume 2 ALPHABETICAL INDEX WORLD HEALTH ORGANIZATION GENEVA 1969 Volume 1 Introduction List of Three-digit Categories Tabular List of Inclusions and Four-digit Sub- categories Medical Certification and Rules for Classification Special Lists for Tabulation Definitions and Recommendations Regulations Volume 2 Alphabetical Index PRINTED IN ENGLAND CONTENTS Introduction Page General arrangement of the Index ....................................... VIII Main sections ............................................................... VIII Structure ..................................................................... IX Code numbzrs .............................................................. x Primary and secondary conditions. ................................... x Multiple diagnoses. ........................................................ XI Spelling....................................................................... XI Order of listing ............................................................. Conventions used in the Index ........................................... XII Parentheses. ................................................................. XII Cross-referexes ........................................................... XI1 Abbreviation NEC. ......................................................
  • Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 1/41

    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole